Lack_of_efficacy_of_high-dose_leucovorin_and_fluorouracil_in_patients_with_advanced_pancreatic_adenocarcinoma._Leucovorin_potentiates_the_cytotoxicity_of_fluorouracil_(5-FU)_in_experimental_tumor_systems_and_appears_to_enhance_the_effectiveness_of_5-FU_in_patients_with_colon_cancer._Twenty-two_eligible_patients_(18_previously_untreated)_with_advanced_pancreatic_adenocarcinoma_were_treated_in_a_phase_II_trial_of_leucovorin_500_mg/m2/d_for_6_days_by_continuous_intravenous_infusion_with_5-FU_370_mg/m2/d_by_rapid_intravenous_injection_on_5_consecutive_days,_beginning_24_hours_after_initiation_of_leucovorin_infusion._Among_the_20_assessable_patients,_there_were_no_complete_or_partial_regressions,_although_there_was_one_minor_response_lasting_4_months._Three_patients_had_stable_disease_for_5,_20,_and_21_months,_respectively._Median_survival_was_10_weeks._Toxicity_was_predominantly_mucosal;_stomatitis_grade_2_or_worse_was_seen_in_five_patients,_and_diarrhea_grade_2_or_worse_was_seen_in_four._Hospitalization_for_toxicity_was_necessary_in_four_previously_untreated_patients_and_three_previously_treated_patients._The_median_WBC_nadir_was_4.6_(range,_1.4_to_9.6)_x_10(3)/microL,_and_the_median_platelet_nadir_was_147.0_(range,_69.0_to_240.0)_x_10(3)/microL._This_combination_of_leucovorin_and_5-FU_did_not_demonstrate_meaningful_therapeutic_activity_in_patients_with_adenocarcinoma_of_the_pancreas_and_was_associated_with_moderate_to_severe_toxicity._It_should_not_be_considered_a_standard_treatment_for_patients_with_this_disease.